After opting in last year, Gilead picks up Kymera's KT-200.
ApexOnco Front Page
Recent articles
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
TLX101 follows Ipax-1 with an apparent success in an academic trial.
TAR-210's latest non-muscle invasive bladder cancer phase 3 setting is post-BCG.
The company scraps nemvaleukin after the latest failure, of Artistry-6.
J&J's new anti-ENPP3 ADC appears – and then disappears – from a clinical study listing.
Meanwhile, Akeso challenges Moderna and BioNTech with an mRNA neoantigen play.
The group could soon provide clarity on CTX112’s regulatory path.
